• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philogen to participate at the Italian Mid Cap Conference organised by Mediobanca on January 19-20, 2022

by last | Jan 5, 2022 | 2022, Past Events

The Italian Midcap Conference provides an opportunity for investors to get a perspective of Philogen progresses and to meet CEO Dario Neri  and CFO Laura Baldi through a series of one-on-one meetings. Mediobanca Italian Mid Cap Conference 

Philogen Q3 2021 Virtual Briefing

by last | Nov 15, 2021 | 2021, Investors, Past Events

Listen to Webcast

Philogen together with the University of Zürich to participate at the 26th Annual Meeting & Education of the Society for Neuro-Oncology on November 18-21, 2021

by last | Nov 8, 2021 | 2021, Past Events

Dr. Tobias Weiss, the Principal Investigator of Fibromun’s programs in brain tumors, is presenting an ePoster entitled “Lomustine and targeted-cytokine therapy: a beneficial liaison for recurrent glioblastoma

Philogen to attend the Connective Tissue Oncology Society (CTOS) Virtual 2021 Annual Meeting on November 10-13, 2021

by last | Nov 7, 2021 | 2021, Past Events

Philogen is presenting a ePoster on the results of the run-in part of the Phase II study with Fibromun plus Dacarbazine for patients with in third or later line advanced/metastatic soft tissue sarcoma. See here for more details.

Philogen to Attend the Festival of Biologics Basel on November 10, 2021

by last | Nov 6, 2021 | 2021, Past Events

Philogen announces its attendance at the Festival of Biologics Basel on November 10, 2021 Lisa Nadal, 3-year PhD student at Philogen, is giving a lecture entitled “A novel IL12-based immunocytokine targeting Fibroblast Activation Protein (FAP) for the treatment...

Philogen to Participate at the 2021 Virtual Stifel Healthcare Conference on November 15-17, 2021

by last | Nov 5, 2021 | Past Events

Stifel Conference provides an opportunity for investors to get a perspective of Philogen progresses and to meet CEO Dario Neri through a series of one-on-one meetings. Co-founder, CEO and CSO, Prof. Dario Neri is giving a 30 minutes presentation on November 16, 2021...
« Older Entries
Next Entries »

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch